In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genmab/GSK: An Impressive Display of Biotech's Increased Leverage

Executive Summary

Cash-rich and product-poor pharmaceutical firms playing catch-up in large molecules have turned 2006 into a bumper year for dealmaking. Even so, Genmab AS's monster December deal with GSK for worldwide rights to the Phase III anti-CD20 antibody ofatumumab (HuMax-CD20), which includes a whopping $459 million in up-front cash and equity payments, seemed to catch analysts by surprise, beating even optimistic expectations
Advertisement

Related Content

Genmab's Star Falls Amid Setbacks, Cuts And Manufacturing Fire-Sale
Arzerra Disappoints In NHL, Putting Genmab On Shaky Ground
Arzerra Disappoints in NHL, Putting Genmab on Shaky Ground
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Big Pharma Breaks the Bank in Late-Stage Licensing
BMS Deals Diabetes Drugs, Solidifies Specialist Stance
A Look Back at 2006: The Pipeline Challenge
A Look Back at 2006: The Pipeline Challenge
GlaxoSmithKline Breaks Out of Its Small-Molecule Mind-Set

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel